Page 10 - நிர்வகித்தல் அறிவியல் ஆசிரியர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

#AANAM – MS Research Focuses on Measuring Therapeutic Lag

Novel method calculates therapeutic lag, which is how long it takes therapies for multiple sclerosis to become fully effective.

United statesIzanne roosUniversity of lisbonUniversity of melbourneUniversity of pittsburghSociety of americaVirtual american academy of neurology annual meetingBiomedical sciencesMultiple sclerosis news todayteamAmerican academyNeurology annualMolecular pathologyMolecular biologyUniversidade nova de lisboaManaging science editorஒன்றுபட்டது மாநிலங்களில்

#AANAM – Vumerity Showing Tolerability, Efficacy in Ongoing RRMS Trial

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Vumerity (diroximel fumarate) continues to be safe and well-tolerated, in addition to reducing measures of disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to updated data from the ongoing EVOLVE-MS-1 Phase 3 clinical trial. Vumerity, developed by Alkermes in collaboration with Biogen, lowers inflammation associated with MS by reducing levels of reactive oxygen species often called free radicals within nerve cells. This is expected to slow disease progression by reducing nerve cell damage. It is similar to Tecfidera (dimethyl fumarate), but is expected to cause fewer gastrointestinal (GI) side effects.

United statesLong beachDiroximel fumarateSibyl wrayUniversity of lisbonAmerican academy of neurologyBiomedical sciencesColumbia universityMultiple sclerosis news todayteamEfficacy outcomesReceived diroximel fumarateAmerican academyMolecular biologyUniversidade nova de lisboaManaging science editorஒன்றுபட்டது மாநிலங்களில்

#AANAM - Ocrevus, Used Early in MS, Helps to Protect Nervous System

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage to the nervous system, new research demonstrates. “We are encouraged by these new analyses showing that early treatment with Ocrevus may significantly control disease progression in both relapsing-remitting MS and in primary progressive MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech (a member of the Roche Group), which makes Ocrevus, said in a press release.

United statesNew yorkLevi garrawayTimothy vollmerGabriel pardoRobert zivadinovUniversity of lisbonBiomedical sciencesOklahoma medical research foundationUniversity of coloradoSociety of americaUniversity of pittsburghAmerican academy of neurologyRoche groupUniversity at buffaloMultiple sclerosis news todayteam

#AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs

#AANAM – Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesLong beachGavin giovannoniSerono merck kgaUniversity of bordeauxUniversity of lisbonSteering committeeAmerican academy of neurologyLondon school of medicineBiomedical sciencesColumbia universityMultiple sclerosis news todayteamLondon schoolAmerican academyLong term efficacyReal world treatment patterns

#AANAM - Ocrevus, Rituximab Linked to More Severe COVID-19 Cases

#AANAM - Ocrevus, Rituximab Linked to More Severe COVID-19 Cases
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesMaria pia sormaniUniversity of genoaUniversity of lisbonUniversity of pittsburghSociety of americaAmerican academy of neurologyBiomedical sciencesMultiple sclerosis news todayteamMultiple sclerosisAmerican academyMolecular pathologyMolecular biologyUniversidade nova de lisboaManaging science editorஒன்றுபட்டது மாநிலங்களில்